

Asymptomatic and subclinical infection of MERS-CoV in persons at the human-camel interface in Saudi Arabia

Khawater Bahkali^{a,b}, Ahmad Albarrag^b, Samy Kasem^c, Ali Al-Hufofi^d, Ali Al-Doweriej^c, Emad Almohammadi^b, Haleemah Alserehi^e, Patrick Nguipdop-Djomo^a, Punam Mangtani^a, Jimmy Whitworth^a, Ada Al-Qunaibet^b

^a Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom. ^b The Saudi Public Health Authority, Riyadh, Saudi Arabia. ^c The National Centre for the Prevention and control of plants, pests and animal diseases, Saudi Arabia ^d Department of Veterinary Laboratory, Ministry of Environment, Water and Agriculture, Saudi Arabia ^e General Directorate of Communicable Diseases Control, Ministry of Health, Saudi Arabia.

Background

- MERS-CoV is a zoonotic virus circulating in camels that causes no noticeable illnesses, yet in humans, it can cause severe disease. ¹
- Transmission is well-documented between humans and animals, yet not human to human, aside from previous outbreaks in healthcare settings, and a constant portion of primary human cases not connected to camels. ²
- Since the SARS-CoV-2 pandemic, there have been suggestions that camels may be at risk of SARS-CoV-2. ³

Aim

To investigate if MERS-CoV can be silently carried by individuals in contact with camels, potentially leading to transmission to people without direct camel exposure.

Objectives

- To measure the prevalence of MERS-CoV using PCR and ELISA in individuals with both direct and indirect contact with camels, and their camels.
- To investigate if SARS-CoV-2 had spilled over from humans to camels.

Methodology

- A cross-sectional study in the central region of Saudi Arabia, between November 2022 and March 2024, in multiple settings at the human-camels interface. Two populations were included:
 - People who have direct (Physical contact, either occupational or recreational) or indirect (being within 10 meters of camels) contact with camels.
 - People who have contact with camel contacts i.e. people in point 1, at least monthly.
- Participants were interviewed in person about demographic and health data, details of contacts with camels and daily contact patterns with people at home, work, etc.
- Sampling was sequential in racetracks, abattoirs, the festival and the OPD, random start then sequential in markets and convenience in a VET clinic.
- Nasal swabs and blood samples were collected from humans and camels; swabs were assayed for MERS-CoV and SARS-CoV-2 nucleic acids by RT-qPCR, and bloods were tested for IgG antibodies against MERS-CoV and SARS-CoV-2 by ELISA.




Figure 1. Flowchart of the study population groups based on the presence around and physical contact with camels.

References

- Memish, Z. A., Perlman, S., Van Kerkhove, M. D. & Zumla, A. Middle East respiratory syndrome. *Lancet* 395, 1063-1077, (2020).
- Khudhair, A. et al. Risk Factors for MERS-CoV Seropositivity among Animal Market and Slaughterhouse Workers, Abu Dhabi, United Arab Emirates, 2014-2017. *Emerg Infect Dis* 25, 927-935, (2019).
- El Masry, I. et al. Serological evidence of SARS-CoV-2 infection in dromedary camels and domestic bovinds in Oman. *Emerg Microbes Infect* 12, 2220577, (2023).

Results

Table 1. Prevalence of MERS-CoV and SARS-CoV-2 RNA and antibodies in camels by age

Assay	Age category	Setting			
		Abattoir d/N (%)	Market d/N (%)	Enclosure d/N (%)	Race/Festival d/N (%)
Anti-MERS-CoV Abs	<1 year	24/30 (80)	30/34 (88.2)	10/20 (50)	6/8 (75)
	1-2 years	5/5 (100)	10/10 (100)	3/4 (75)	11/15 (73.3)
	>2 years	1/1 (100)	79/80 (98.8)	38/38 (100)	46/46 (100)
	Total	30/72 (41.7)	125/254 (49.2)	53/126 (42.1)	82/160 (51.3)
MERS RNA	<1 year	43/46 (93.5)	17/36 (47.2)	15/39 (38.5)	1/8 (12.5)
	1-2 years	16/18 (88.9)	4/10 (40)	0/4	0/12
	>2 years	5/7 (71.4)	35/83 (42.2)	6/56 (10.7)	0/44
	Total	64/71 (90.1)	57/135 (42.2)	22/101 (21.8)	1/74 (1.4)

- SARS-CoV-2 RNA was **not found** in nasal swabs from 381 camels.
- No** anti-SARS-CoV-2 antibodies were found in sera from 321 camels.

Table 2. Characteristics of human study population

Variable	Gr1: No contact (n=37)	Gr2: Non occupational (n=140)	Gr3: Occupational (Abattoir) (n=113)	Gr4: Occupational (Open-air) (n=218)
Age (years), Median (IQR)	n (%)	n (%)	n (%)	n (%)
Age categories	34 (17.5)	37 (15)	35 (12)	33 (15)
13_39	24 (69%)	76 (54.3%)	81 (71.7%)	144 (66.1%)
40_59	10 (29%)	49 (35%)	29 (25.7%)	65 (29.8%)
>60	1 (2.8%)	12 (8.6%)	3 (2.7%)	5 (2.3%)
Sex				
Female	14 (37.8%)	10 (7.1%)	0	0
Male	23 (62.2%)	130 (92.9%)	113 (100%)	218 (100%)
Nationality				
Saudi	28 (75.7%)	100 (81.3%)	1 (0.9%)	29 (14.1%)
Non-Saudi	9 (24.3%)	23 (18.6%)	112 (99.1%)	176 (85.9%)
Covid-19 Vax (≥1 dose)				
No	1 (4.2%)	9 (7.8%)	2 (1.8%)	45 (23%)
Yes	23 (95.8%)	105 (92%)	107 (98.2%)	151 (77%)

Table 3. Prevalence of MERS-CoV RNA and anti-MERS antibodies in humans

Contact with camels	PCR (orf1)		S1 IgG Abs			
	n/N	% (95% CI)	ODR ≥ 1.1		ODR ≥ 0.5	
Gr1: No contact	0/21	---	2/36	5.6 (0;13)	9/36	25 (10.9;39.1)
Gr2: Non occupational	0/113	---	1/122	0.8 (0;2.4)	23/122	18.9 (11.9;25.8)
Gr3: In Abattoir	2/113*	1.8 (0;4.2)	4/113	3.5 (0.1;6.9)	50/113	44.2 (35.1;53.4)
Gr4: In Open-air	2/204*	1 (0;2.3)	6/187	3.2 (0.7;5.7)	33/187	17.6 (12.2;23.1)

Note: *The PCR Ct values for the 4 samples were between 37 and 39 cycles (Orf gene), when repeated with new extractions from original samples, for both MERS (E & Orf gene), only one detected at Ct 37 in Gr 4.

Conclusion

- 13 and 115 out of 508 individuals were identified with MERS-CoV exposure or past infection using ELISA cutoffs of 1.1 and 0.5 respectively.
- However, cross-reactivity with SARS-CoV-2 needs to be ruled out by confirmatory neutralization test.
- RNA detection was confirmed in one individual (CT=37) and probable in three others worked with camels, none of them had severe symptoms in the previous two weeks.

Limitations

- Serology cutoffs challenges: higher cutoffs reduce sensitivity, lower cutoffs reduce specificity, leading to false positives.
- PCR results might underestimate prevalence, lower respiratory samples are more accurate than upper ones, especially in mild infections.
- Non-random sampling and clustering requires caution in interpreting representativeness.

